Merck & Co Inc MRK
News
Summit Therapeutics Shares Triple After Drug Candidate Data
Trending: Merck to Buy Biotech Company EyeBio for $1.3 Billion
Merck could pay up to $3 billion to boost its retinal disease candidate pipeline
FDA Grants Priority Review to Merck’s Application for KEYTRUDA® (pembrolizumab) Plus Chemotherapy as First-Line Treatment of Patients With Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma
Merck to Acquire EyeBio for $1.3 Billion
Merck to Acquire EyeBio
Merck Announces Third-Quarter 2024 Dividend
Merck On Track for Largest Percent Decrease Since October 2023 — Data Talk
Merck Announces Phase 3 KEYNOTE-522 Trial Met its Overall Survival (OS) Endpoint in Patients With High-Risk Early-Stage Triple Negative Breast Cancer (TNBC)
Merck to Present New Data at 2024 ASCO Annual Meeting Demonstrating Advancements in Novel Oncology Treatment Approaches Across Broad Portfolio and Diverse Pipeline
Merck Ends Co-Formulation Arm of Keytruda High-Risk Melanoma Study
Merck Provides Update on Phase 3 KeyVibe-010 Trial Evaluating an Investigational Coformulation of Vibostolimab and Pembrolizumab as Adjuvant Treatment for Patients With Resected High-Risk Melanoma
Merck Study of Keytruda With Chemotherapy in Endometrial Cancer Fails to Meet Endpoint
Merck Provides Update on Phase 3 KEYNOTE-B21 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Chemotherapy, With or Without Radiotherapy, for Patients With Newly Diagnosed, High-Risk Endometrial Cancer After Surgery With Curative Intent
Merck Expands Access to High-Quality Maternal Care for More Than 30 Million Women Worldwide Through Merck for Mothers
Mitigating Muscle Loss Becoming More Vital, Global Cancer Cachexia Market Projected to Reach $3.3 Billion in 2024
Merck to Participate in the Bank of America Securities 2024 Healthcare Conference
Merck Currently Down Six Consecutive Days, on Pace for Longest Losing Streak Since September 2023 — Data Talk
Merck Announces Phase 3 KEYNOTE-811 Trial Met Dual Primary Endpoint of Overall Survival (OS) as First-Line Treatment in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma